ClinicalTrials.gg
CompletedNCT00500357Updated Apr 19, 2011Results posted

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 16 sites in South Africa. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-04-19.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Study summary

This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to subjects who have already received one dose of 13vPnC, and one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) one year later. This study will determine if a subsequent dose of 13vPnC one year later results in similar or greater immune response (body's ability to protect against disease) than that measured after the initial dose of 13vPnC.

02

Conditions studied

  • Vaccines, Pneumococcal Conjugate Vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • Previous participant of study 6115A1-500 and received 13vPnC +AlPO4 / 23vPS
  • Generally healthy male or female adults 65 years of age or older
  • Available for the duration of the trial - approximately 1 month
  • No history of severe adverse reaction associated with a vaccine

    • score less than or equal to 21 was an exclusion criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)

Secondary outcomes

  1. Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)

    Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)

  2. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)

    Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)

  3. Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)

    Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)

Other outcomes

  1. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)

    Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move shoulder).

    Time frame: Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)

  2. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)

    Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Aggravated muscle pain, New joint pain, and Aggravated joint pain.

    Time frame: Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)

07

Results

Posted Feb 17, 2011

Participant flow

915 participants were enrolled in core study NCT00269672 (6115A1-500); 914 participants received 13-valent pneumococcal conjugate vaccine plus or minus aluminum phosphate (13vPnC+AlPO4 or 13vPnC-AlPO4) or 23-valent pneumococcal polysaccharide vaccine (23vPS) in Year 0 (Vaccination 1 \[Vax 1\]) followed by 13vPnC+AlPO4 or 23vPS in Year 1 (Vax 2).

Participant flow — Overall Study
Milestone13vPnC (Vax 3 Follow-up / NCT00500357)
Started105
Received 13vpnc (vax 3)105
Evaluable immunogenicity population98
Completed104
Not completed1
Withdrew: Death1

Outcome measures

PrimaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)
geometric mean titer13vPnC (Vax 1 Core Study/NCT00269672)13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)
Serotype 1198 (133.7 to 293.0)78 (55.4 to 108.8)
Serotype 3126 (94.2 to 167.8)104 (81.5 to 132.5)
Serotype 42210 (1603.5 to 3045.2)1254 (926.6 to 1695.7)
Serotype 5413 (278.0 to 614.9)170 (119.7 to 241.3)
Serotype 6A4931 (3391.0 to 7170.8)3158 (2369.3 to 4209.7)
Serotype 6B3251 (2105.0 to 5019.6)2440 (1753.2 to 3395.1)
Serotype 7F869 (540.3 to 1398.0)353 (221.7 to 561.0)
Serotype 9V977 (588.6 to 1620.4)247 (142.9 to 426.8)
Serotype 14982 (676.0 to 1425.8)550 (392.5 to 769.8)
Serotype 18C2860 (1899.9 to 4304.6)1457 (1057.8 to 2008.1)
Serotype 19A1141 (832.4 to 1564.3)431 (340.3 to 546.1)
Serotype 19F1014 (654.4 to 1572.6)494 (341.4 to 715.5)
Serotype 23F523 (315.4 to 867.7)661 (443.6 to 985.8)
Statistical analysis
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.4 · 95% CI 0.28 to 0.56Confidence Intervals (CI) for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 minus \[-\] Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.8 · 95% CI 0.67 to 1.01CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.6 · 95% CI 0.44 to 0.72CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.4 · 95% CI 0.32 to 0.53CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.6 · 95% CI 0.45 to 0.91CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.8 · 95% CI 0.56 to 1.01CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.4 · 95% CI 0.25 to 0.65CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.3 · 95% CI 0.16 to 0.40CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.6 · 95% CI 0.40 to 0.78CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.5 · 95% CI 0.40 to 0.65CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.4 · 95% CI 0.30 to 0.48CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.5 · 95% CI 0.35 to 0.67CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 1.3 · 95% CI 0.86 to 1.86CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 1).
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)

Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move shoulder).

Time frame:
Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)
percentage of participants13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up/NCT00500357)
Redness: Any (n=79)7.6
Redness: Mild (n=79)6.3
Redness: Moderate (n=78)3.8
Redness: Severe (n=78)0.0
Swelling: Any (n=83)16.9
Swelling: Mild (n=81)12.3
Swelling: Moderate (n=81)8.6
Swelling: Severe (n=78)0.0
Pain: Any (n=89)40.4
Pain: Mild (n=88)34.1
Pain: Moderate (n=83)15.7
Pain: Severe (n=78)0.0
Limitation of arm movement: Any (n=80)11.3
Limitation of arm movement: Mild (n=80)8.8
Limitation of arm movement: Moderate (n=78)2.6
Limitation of arm movement: Severe (n=79)1.3
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)

Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Aggravated muscle pain, New joint pain, and Aggravated joint pain.

Time frame:
Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)
percentage of participants13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up/NCT00500357)
Fever: Any ≥38 degrees C (n=81)7.4
Fever: Mild ≥38 but <38.5 degrees C (n=80)3.8
Fever: Moderate ≥38.5 but <39 degrees C (n=78)2.6
Fever: Severe ≥39 but ≤40 degrees C (n=80)2.5
Potentially life-threatening >40 degrees C (n=79)1.3
Fatigue (n=83)27.7
Headache (n=81)19.8
Chills (n=79)8.9
Rash (n=78)2.6
Vomiting (n=79)1.3
Decreased appetite (n=82)18.3
New muscle pain (n=84)21.4
Aggravated muscle pain (n=80)12.5
New joint pain (n=78)7.7
Aggravated joint pain (n=79)6.3
SecondaryPneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)

Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Reported as:
Geometric mean · geometric mean titer
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)
geometric mean titer13vPnC / 23vPS (Vax 2 Core Study/NCT00269672)13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)
Serotype 1184 (136.2 to 249.2)81 (58.3 to 112.5)
Serotype 3131 (102.2 to 168.9)104 (81.5 to 132.5)
Serotype 41457 (1092.8 to 1942.2)1406 (1098.1 to 1799.8)
Serotype 5326 (228.4 to 464.0)219 (153.6 to 312.8)
Serotype 6A1732 (1163.1 to 2580.0)3443 (2678.7 to 4425.1)
Serotype 6B1862 (1333.5 to 2600.7)2505 (1798.8 to 3488.1)
Serotype 7F1292 (925.2 to 1803.5)351 (224.5 to 550.1)
Serotype 9V624 (371.0 to 1051.1)267 (153.9 to 463.0)
Serotype 14808 (599.4 to 1089.7)557 (399.0 to 778.9)
Serotype 18C1753 (1214.9 to 2528.5)1452 (1049.6 to 2009.0)
Serotype 19A756 (581.2 to 983.9)511 (408.5 to 639.1)
Serotype 19F901 (689.1 to 1177.3)527 (369.1 to 752.7)
Serotype 23F484 (323.7 to 723.6)731 (499.0 to 1071.9)
Statistical analysis
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.4 · 95% CI 0.34 to 0.57CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.8 · 95% CI 0.66 to 0.95CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 1.0 · 95% CI 0.76 to 1.22CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.7 · 95% CI 0.57 to 0.80CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 2.0 · 95% CI 1.39 to 2.84CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 1.3 · 95% CI 1.11 to 1.63CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.3 · 95% CI 0.18 to 0.41CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.4 · 95% CI 0.27 to 0.68CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.7 · 95% CI 0.57 to 0.83CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.8 · 95% CI 0.66 to 1.03CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.7 · 95% CI 0.58 to 0.78CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.6 · 95% CI 0.47 to 0.73CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 1.5 · 95% CI 1.18 to 1.94CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)

Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Reported as:
Geometric mean · geometric mean concentration (mcg/mL)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)
geometric mean concentration (mcg/mL)13vPnC (Vax 1 Core Study/NCT00269672)13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)
Serotype 17.67 (5.48 to 10.72)4.99 (4.06 to 6.14)
Serotype 32.60 (2.04 to 3.33)1.35 (1.12 to 1.62)
Serotype 44.68 (3.40 to 6.43)2.96 (2.30 to 3.81)
Serotype 519.51 (13.92 to 27.36)6.33 (5.08 to 7.90)
Serotype 6A9.12 (6.70 to 12.42)8.22 (6.30 to 10.72)
Serotype 6B13.03 (9.11 to 18.62)10.32 (8.10 to 13.14)
Serotype 7F6.93 (5.45 to 8.81)5.02 (4.23 to 5.95)
Serotype 9V11.56 (8.68 to 15.40)5.77 (4.70 to 7.09)
Serotype 1417.51 (12.70 to 24.13)13.34 (10.67 to 16.69)
Serotype 18C20.59 (15.35 to 27.62)7.82 (6.39 to 9.56)
Serotype 19A29.52 (22.14 to 39.36)17.80 (14.67 to 21.60)
Serotype 19F13.39 (9.47 to 18.92)8.55 (6.60 to 11.07)
Serotype 23F10.16 (7.06 to 14.64)7.73 (5.77 to 10.36)
Statistical analysis
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.65 · 95% CI 0.52 to 0.82CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.52 · 95% CI 0.43 to 0.62CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.63 · 95% CI 0.53 to 0.76CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.32 · 95% CI 0.27 to 0.39CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.90 · 95% CI 0.74 to 1.10CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.79 · 95% CI 0.63 to 0.99CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.72 · 95% CI 0.60 to 0.87CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.50 · 95% CI 0.42 to 0.60CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.76 · 95% CI 0.59 to 0.98CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.38 · 95% CI 0.31 to 0.46CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.60 · 95% CI 0.49 to 0.74CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.64 · 95% CI 0.52 to 0.79CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
  • 13vPnC (Vax 1 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.76 · 95% CI 0.62 to 0.93CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of concentrations (Vax 3 - Vax 1).
SecondaryPneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)

Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Reported as:
Geometric mean · geometric mean concentration (mcg/mL)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)
geometric mean concentration (mcg/mL)13vPnC / 23vPS (Vax 2 Core Study/NCT00269672)13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)
Serotype 17.29 (5.96 to 8.93)4.99 (4.06 to 6.14)
Serotype 32.46 (2.01 to 3.01)1.36 (1.13 to 1.64)
Serotype 43.93 (3.03 to 5.11)2.96 (2.30 to 3.81)
Serotype 59.29 (7.37 to 11.71)6.33 (5.08 to 7.90)
Serotype 6A5.51 (4.25 to 7.15)8.22 (6.30 to 10.72)
Serotype 6B9.67 (7.47 to 12.53)10.32 (8.10 to 13.14)
Serotype 7F7.41 (6.07 to 9.04)5.02 (4.23 to 5.95)
Serotype 9V9.60 (7.68 to 12.00)5.77 (4.70 to 7.09)
Serotype 1422.67 (17.89 to 28.72)13.34 (10.67 to 16.69)
Serotype 18C11.66 (9.66 to 14.07)7.82 (6.39 to 9.56)
Serotype 19A22.78 (18.47 to 28.11)17.80 (14.67 to 21.60)
Serotype 19F15.82 (11.97 to 20.91)8.55 (6.60 to 11.07)
Serotype 23F7.27 (5.52 to 9.57)7.73 (5.77 to 10.36)
Statistical analysis
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.68 · 95% CI 0.60 to 0.78CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.55 · 95% CI 0.48 to 0.64CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.75 · 95% CI 0.65 to 0.87CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.68 · 95% CI 0.61 to 0.76CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 1.49 · 95% CI 1.27 to 1.75CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 1.07 · 95% CI 0.94 to 1.21CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.68 · 95% CI 0.58 to 0.79CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.60 · 95% CI 0.53 to 0.68CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.59 · 95% CI 0.51 to 0.67CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.67 · 95% CI 0.60 to 0.74CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.78 · 95% CI 0.69 to 0.88CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 0.54 · 95% CI 0.47 to 0.62CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).
  • 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) vs 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) · Geometric mean fold rise: 1.06 · 95% CI 0.90 to 1.25CI for the GMFR was a back transformation of a CI based on the Student t distribution for the mean difference of the logarithms of titers (Vax 3 - Vax 2).

Adverse events

Collected over Baseline / Day 1 up to 43 days postvaccination. Local Reactions and Systemic Events assessed within 14 days of vaccination.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study)—2/105 (1.9%)46/105 (43.8%)
13vPnC+AlPO4 (After Vax 1 Core Study)—2/308 (0.6%)70/308 (22.7%)
13vPnC-AlPO4 (After Vax 1 Core Study)—4/304 (1.3%)58/304 (19.1%)
23vPS (After Vax 1 Core Study)—1/302 (0.3%)80/302 (26.5%)
13vPnC+AlPO4/13vPnC+AlPO4 (After Vax 2 Core Study)—3/139 (2.2%)26/139 (18.7%)
13vPnC+AlPO4/23vPS (After Vax 2 Core Study)—1/128 (0.8%)35/128 (27.3%)
13vPnC-AlPO4/23vPS (After Vax 2 Core Study)—1/273 (0.4%)76/273 (27.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
Event13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study)13vPnC+AlPO4 (After Vax 1 Core Study)13vPnC-AlPO4 (After Vax 1 Core Study)23vPS (After Vax 1 Core Study)13vPnC+AlPO4/13vPnC+AlPO4 (After Vax 2 Core Study)13vPnC+AlPO4/23vPS (After Vax 2 Core Study)13vPnC-AlPO4/23vPS (After Vax 2 Core Study)
Cardio-respiratory arrestCardiac disorders1/105——————
Hip fractureInjury, poisoning and procedural complications1/105——————
ArthralgiaMusculoskeletal and connective tissue disorders—0/3080/3040/3020/1391/1280/273
PhimosisCongenital, familial and genetic disorders—0/3080/3040/3021/1390/1280/273
Intervertebral disc disorderMusculoskeletal and connective tissue disorders—0/3080/3040/3021/1390/1280/273
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)—0/3080/3040/3021/1390/1280/273
HydrocephalusNervous system disorders—0/3080/3040/3021/1390/1280/273
Myocardial infarctionCardiac disorders—0/3081/3040/3020/1390/1281/273
ExostosisMusculoskeletal and connective tissue disorders—0/3080/3041/3020/1390/1280/273
Spinal osteoarthritisMusculoskeletal and connective tissue disorders—0/3080/3041/3020/1390/1280/273
Most frequent other events
Showing 10 of 158
Most frequent other events
Event13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study)13vPnC+AlPO4 (After Vax 1 Core Study)13vPnC-AlPO4 (After Vax 1 Core Study)23vPS (After Vax 1 Core Study)13vPnC+AlPO4/13vPnC+AlPO4 (After Vax 2 Core Study)13vPnC+AlPO4/23vPS (After Vax 2 Core Study)13vPnC-AlPO4/23vPS (After Vax 2 Core Study)
Pain (any)Skin and subcutaneous tissue disorders36/89——————
Pain (mild)Skin and subcutaneous tissue disorders30/88——————
FatigueGeneral disorders23/83——————
New muscle painGeneral disorders18/84——————
HeadacheGeneral disorders16/81——————
Decreased appetitieGeneral disorders15/82——————
Swelling (any)Skin and subcutaneous tissue disorders14/83——————
Pain (moderate)Skin and subcutaneous tissue disorders13/83——————
Aggravated muscle painGeneral disorders10/80——————
Swelling (mild)Skin and subcutaneous tissue disorders10/81——————

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC (Vax 3 Follow-up / NCT00500357)
Mean72.8 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC (Vax 3 Follow-up / NCT00500357)
Female56
Male49
08

Study locations

16 sites
  • Amanzimtoti, 4126, South Africa
  • Bishop Lavis, 7490, South Africa
  • Bloemfontein, 9317, South Africa
  • Brits, 0250, South Africa
  • Cape Town, 7941, South Africa
  • Cape Town, 7945, South Africa
  • Lenasia, 1827, South Africa
  • Paarl, 7646, South Africa
  • Parow, 7500, South Africa
  • Parys, 9585, South Africa
  • Pretoria, 0002, South Africa
  • Pretoria, 0082, South Africa
  • Pretoria, 0083, South Africa
  • Pretoria, 0183, South Africa
  • Scottburgh South, 4180, South Africa
  • Vanderbijlpark, 1911, South Africa
09

References and documents

Publications

  • Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Hum Vaccin Immunother. 2014;10(5):1343-53. doi: 10.4161/hv.27998. Epub 2014 Feb 27. PubMed 24576885 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 1 month after primary completion. A results delay was requested in Jan 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2007
First posted
Jul 12, 2007
Start
Nov 2007
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results delay requested
Jan 21, 2009
Results first posted
Feb 17, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00500357
First posted
Jul 12, 2007
Start date
Nov 2007
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Feb 17, 2011
Last update
Apr 19, 2011

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion